Tin tức & Cập nhật

Disease activity, as measured by C-reactive protein (CRP), foecal calprotectin (FC), and endoscopic evaluation, does not significantly vary a year following the initiation of gender-affirming hormone (GAH) therapy in transgender and gender nonconforming patients with inflammatory bowel disease (IBD), as shown in a study presented at AIBD 2024.

The addition of the CDK4/6 inhibitor palbociclib to anti-HER2 and endocrine therapy (ET) significantly improves progression-free survival (PFS) in patients with hormone receptor-positive, HER-positive (HR+, HER+) metastatic breast cancer (mBC) in the first-line setting, according to the results of the phase III AFT-38 PATINA trial.

The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naïve (TN) chronic lymphocytic leukaemia (CLL).

In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).